Printer Friendly

DEPRENYL RESEARCH LIMITED ANNOUNCES NEW APPOINTMENTS

 DEPRENYL RESEARCH LIMITED ANNOUNCES NEW APPOINTMENTS
 TORONTO, Aug. 31 /PRNewswire/ -- The board of directors and


management of Deprenyl Research Limited (NASDAQ: DEPLF) today announced the appointments of Sen. Stanley Haidasz and Martin Siegerman as directors of corporate development. Their initial duties will be to serve on an investment advisory committee.
 Sen. Stanley Haidasz sits on the Senate Banking Trade & Commerce committee, he is on the board of directors of Noram Capital and Copernicus Senior Citizens Lodge.
 Martin Siegerman is retired. He was formerly deputy chairman of the Royal Bank Investment Management Inc. Prior to that he was president of United Bond and Share Ltd. and Roy Funds. Until Aug. 1, 1992, he was advisor to RBIM Inc.
 Deprenyl Research Limited is a Canadian pharmaceutical company specializing in products for neurologic diseases, other chronic conditions and dermatology.
 -0- 8/31/92
 /CONTACT: Martin Barkin, M.D., president of Deprenyl Research Limited, 416-537-4372, or (fax) 416-537-1653, or Irving L. Straus, chairman of Straus Corporate Communications, 212-768-2477, or (fax) 212-768-2476, for Deprenyl Research/
 (DEPLF) CO: Deprenyl Research Limited ST: Ontario IN: MTC SU: PER


TS-SM -- NY040 -- 4923 08/31/92 11:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 31, 1992
Words:190
Previous Article:FEDERAL EMERGENCY RESPONSE TEAMS ARRIVE IN GUAM
Next Article:MOODY'S COMMENTS ON LOCAL CREDITS IN NEW JERSEY; IMPLICATION OF NEW JERSEY RATING DOWNGRADE FOR LOCAL UNITS
Topics:


Related Articles
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH SETS THE FACTS STRAIGHT
DEPRENYL RESEARCH ELECTS MARTIN BARKIN PRESIDENT, CHIEF OPERATING OFFICER AND DIRECTOR
DEPRENYL ACQUIRES CONTROL OF QUEBEC-BASED LIPOPHARM INC.
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
MARTIN BARKIN NAMED CEO OF DEPRENYL RESEARCH LIMITED MORTON SHULMAN TO REMAIN CO-CHAIRMAN
CANADIAN LICENSE FOR NEW NEUROLOGY DRUG ACQUIRED BY DEPRENYL RESEARCH LIMITED FROM LABORATOIRE L. LAFON OF FRANCE
DEPRENYL RESEARCH LIMITED ANNOUNCES ELDEPRYL(R) LISTED ON THE ONTARIO DRUG BENEFIT FORMULARY
DEPRENYL RESEARCH LIMITED ANNOUNCES RETIREMENT OF DR. MORTON SHULMAN

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters